PHOENIX ― Gastrointestinal cancers are some of the most commonly diagnosed cancers, and they continue to be associated with poor survival outcomes. The drug adagrasib specifically targets the KRASG12C gene mutation that is common in gastrointestinal cancers and inhibits gastrointestinal function.
Trending
- Behavioral Interventions Improve Mailed Colorectal Cancer Screening Among Overdue Patients in a Randomized Trial (CGH Journal)
- Leading efforts in insurance oversight (AGA)
- Different outcomes of AI-read vs human-read endoscopies in the TITRATE study (Medicom)
- Firefly-Inspired Pill Lights Up the Gut To Reveal Inflammation (Technology Networks)
- Private equity investment: Could it help physicians? (Medical Economics)
- Olympus execs talk about import alert, GI robot and AI (Medtech Dive)
- Breath Test for MASH/MASLD Shows Promise in Pilot Study (GI & Endoscopy News)
- With A Doctor Shortage; Is Concierge Medicine Morally Acceptable? (Forbes)
